King's College London

Research portal

Psychedelics in the treatment of unipolar mood disorders: A systematic review

Research output: Contribution to journalArticle

James J H Rucker ; Luke A. Jelen ; Sarah Flynn ; Kyle D. Frowde ; Allan H. Young

Original languageEnglish
Pages (from-to)1220-1229
Number of pages10
JournalJournal of psychopharmacology (Oxford, England)
Volume30
Issue number12
Early online date19 Nov 2016
DOIs
StatePublished - 1 Dec 2016

Documents

King's Authors

Abstract

Unipolar mood disorders, including major depressive disorder and persistent depressive disorder (dysthymia), confer high rates of disability and mortality and a very high socioeconomic burden. Current treatment is suboptimal in most cases and there is little of note in the pharmaceutical development pipeline. The psychedelic drugs, including lysergic acid diethylamide and psilocybin, were used extensively in the treatment of mood disorders, and other psychiatric conditions, before their prohibition in the late 1960s. They are relatively safe when used in medically controlled environments, with no reported risk of dependence. Here, we present a systematic review of published clinical treatment studies using psychedelics in patients with broadly defined UMD, and consider their place in psychiatry. Whilst all of the included studies have methodological shortcomings, of 423 individuals in 19 studies, 335 (79.2%) showed clinician-judged improvement after treatment with psychedelics. A recently completed pilot study in the UK favours the use of psilocybin with psychological support in treatment resistant depressive disorder. The evidence overall strongly suggests that psychedelics should be re-examined in modern clinical trials for their use in unipolar mood disorders and other non-psychotic mental health conditions.

Download statistics

No data available

View graph of relations

© 2015 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454